Deciphera Pharmaceuticals, Inc. DCPH NASDAQ

NASDAQ Global Select • Healthcare • Drug Manufacturers - Specialty & Generic • US • USD

SharesGrow Score

51/100

2/7 Pass

SharesGrow Intrinsic Value

Ha habido 50 transacciones internas recientes registradas para Deciphera Pharmaceuticals, Inc. (DCPH), incluyendo 27 compras y 22 ventas. El total de compras internas fue valorado en $12.24M y el total de ventas internas en $1.51M.

Internos destacados con actividad reciente incluyen Brightstar Associates Llc, Sherman Matthew L, Kelly Thomas Patrick. Las transacciones internas pueden proporcionar información sobre cómo la dirección de la empresa ve la valoración y perspectivas futuras de la acción.

Operaciones de Insiders — DCPH

Fecha	Nombre	Cargo	Tipo de Transacción	Acciones	Precio Promedio	Valor	Acciones en Propiedad
2024-04-22	Brightstar Associates Llc	10 Percent Owner	Ejercicio de Opciones (ITM)	48,136	$0.01	$481.36	-
2024-02-16	Sherman Matthew L	EVP & Chief Medical Officer	Venta Informativa	2,615	$15.62	$40.84K	108,739
2024-02-16	Kelly Thomas Patrick	Chief Financial Officer	Venta Informativa	3,010	$15.62	$47.01K	80,350
2024-02-16	Martin Daniel C.	Chief Commercial Officer	Venta Informativa	2,267	$15.62	$35.41K	55,118
2024-02-16	Pitman Jama	SVP, Chief Development Officer	Venta Informativa	2,267	$15.62	$35.41K	68,031
2024-02-15	Sherman Matthew L	EVP & Chief Medical Officer	Concesión de RSU	69,100	$15.92	$1.1M	69,100
2024-02-15	Kelly Thomas Patrick	Chief Financial Officer	Concesión de RSU	69,100	$15.92	$1.1M	69,100
2024-02-15	Hoerter Steven L.	President and CEO	Concesión de RSU	298,100	$15.92	$4.75M	298,100
2024-02-15	Martin Daniel C.	Chief Commercial Officer	Concesión de RSU	38,900	$15.92	$619.29K	38,900
2024-02-15	Dhanak Dashyant	EVP & Chief Scientific Officer	Concesión de RSU	69,100	$15.92	$1.1M	69,100
2024-02-15	Pitman Jama	SVP, Chief Development Officer	Concesión de RSU	38,900	$15.92	$619.29K	38,900
2024-02-07	Brightstar Associates Llc	10 Percent Owner	Ejercicio de Opciones (ITM)	914,001	$0.01	$9.14K	48,136
2024-01-16	Sherman Matthew L	EVP & Chief Medical Officer	Venta Informativa	2,435	$14.47	$35.23K	94,079
2024-01-16	Allen Patricia L	Director	Concesión de RSU	4,727	$14.46	$68.35K	4,727
2024-01-16	Kelly Thomas Patrick	Chief Financial Officer	Venta Informativa	2,435	$14.47	$35.23K	66,085
2024-01-16	Squarer Ron	Director	Concesión de RSU	4,727	$14.46	$68.35K	4,727
2024-01-16	Walsh Dennis Leo	Director	Concesión de RSU	4,727	$14.46	$68.35K	4,727
2024-01-16	Martin Daniel C.	Chief Commercial Officer	Venta Informativa	1,624	$14.47	$23.5K	47,660
2024-01-16	Friedman Franklin Stuart	Director	Concesión de RSU	4,727	$14.46	$68.35K	4,727
2024-01-16	Pitman Jama	SVP, Chief Development Officer	Venta Informativa	1,624	$14.47	$23.5K	50,573
2023-12-13	Sherman Matthew L	EVP & Chief Medical Officer	Venta Informativa	2,792	$15.37	$42.9K	96,514
2023-12-13	Kelly Thomas Patrick	Chief Financial Officer	Venta Informativa	2,792	$15.37	$42.9K	68,520
2023-12-13	Hoerter Steven L.	President and CEO	Venta Informativa	30,664	$15.37	$471.22K	72,763
2023-12-13	Martin Daniel C.	Chief Commercial Officer	Venta Informativa	1,727	$15.37	$26.54K	49,284
2023-12-13	Pitman Jama	See Remarks	Venta Informativa	1,662	$15.37	$25.54K	52,197
2023-12-12	Sherman Matthew L	EVP & Chief Medical Officer	Concesión de RSU	8,244	-	-	99,306
2023-12-12	Kelly Thomas Patrick	Chief Financial Officer	Concesión de RSU	8,244	-	-	71,312
2023-12-12	Hoerter Steven L.	President and CEO	Concesión de RSU	62,500	-	-	103,427
2023-12-12	Martin Daniel C.	Chief Commercial Officer	Concesión de RSU	5,576	-	-	51,011
2023-12-12	Pitman Jama	See Remarks	Concesión de RSU	5,576	-	-	53,859
2023-11-30	Martin Daniel C.	Chief Commercial Officer	Venta Informativa	17,801	$12.57	$223.76K	45,435
2023-10-30	Sherman Matthew L	EVP & Chief Medical Officer	Venta Informativa	2,360	$12.02	$28.36K	90,628
2023-10-30	Kelly Thomas Patrick	Chief Financial Officer	Venta Informativa	2,316	$12.02	$27.83K	63,068
2023-10-30	Hoerter Steven L.	President and CEO	Venta Informativa	21,573	$12.02	$259.26K	40,927
2023-10-30	Martin Daniel C.	Chief Commercial Officer	Venta Informativa	1,407	$12.02	$16.91K	62,884
2023-10-30	Pitman Jama	See Remarks	Venta Informativa	1,407	$12.02	$16.91K	48,283
2023-10-28	Sherman Matthew L	EVP & Chief Medical Officer	Concesión de RSU	8,244	-	-	92,988
2023-10-28	Kelly Thomas Patrick	Chief Financial Officer	Concesión de RSU	8,244	-	-	65,384
2023-10-28	Hoerter Steven L.	President and CEO	Concesión de RSU	62,500	-	-	62,500
2023-10-28	Martin Daniel C.	Chief Commercial Officer	Concesión de RSU	5,576	-	-	64,291
2023-10-28	Pitman Jama	See Remarks	Concesión de RSU	5,576	-	-	49,690
2023-10-02	Sherman Matthew L	EVP & Chief Medical Officer	Venta Informativa	2,942	$12.68	$37.3K	84,744
2023-09-15	Dhanak Dashyant	EVP & Chief Scientific Officer	Concesión de RSU	65,900	-	-	65,900
2023-09-05	Dhanak Dashyant	Officer	Desconocido	-	-	-	-
2023-06-21	Allen Patricia L	Director	Concesión de RSU	30,000	$14.91	$447.3K	30,000
2023-06-21	Squarer Ron	Director	Concesión de RSU	30,000	$14.91	$447.3K	30,000
2023-06-21	Kelley Susan L.	Director	Concesión de RSU	30,000	$14.91	$447.3K	30,000
2023-06-21	Benz Edward J. Jr	Director	Concesión de RSU	30,000	$14.91	$447.3K	30,000
2023-06-21	Walsh Dennis Leo	Director	Concesión de RSU	30,000	$14.91	$447.3K	30,000
2023-06-21	Martin John Richard	Director	Concesión de RSU	30,000	$14.91	$447.3K	30,000

■ Informativa — transacción en mercado abierto (más significativa) ■ No informativa (compra) — premio, ejercicio de opción, conversión ■ No informativa (venta) — retención fiscal, venta de adjudicación ■ Neutral — regalo, fideicomiso, vencimiento